Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Start Date
2/18/2026
Completion Date
2/1/2029
Summary
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD
Eligibility Criteria
Age Range: 50 years to 85 years
Conditions
Locations
CND Clinical Research Center
Scottsdale, Arizona 85258
United States
Movement Disorders Center of Arizona
Scottsdale, Arizona 85258
United States
Neurology One
Orlando, Florida 32825
United States
University of Kansas Medical Center
Kansas City, Kansas 66160
United States
Norton Healthcare
Louisville, Kentucky 40202
United States
Quest Research Institute
Farmington Hills, Michigan 48334
United States
Veracity Neurosciences LLC
Memphis, Tennessee 38157
United States
Vanderbilt University Medical Center
Nashville, Tennessee 37232
United States